



ASX Release

3 April 2024

Launch of Dapsone 5%, Gel in the United States

Melbourne, Australia; Acrux Limited (ASX:ACR)

Acrux and its partner TruPharma today announced the launch of a generic of Dapsone 5%, Gel in the United States.

Dapsone 5%, Gel is a prescription medicine used on your skin (topical) to treat acne vulgaris.

CEO and Managing Director of Acrux, Michael Kotsanis, said “We are excited to partner with TruPharma to launch this topical prescription product in the United States. This is another product from the Acrux pipeline that is being commercialised. We look forward to announcing additional regulatory approvals and launches in the future”.

Annual market sales for Dapsone 5%, Gel products for the 12 months ending October 2023 exceeded US\$15 million as measured by IQVIA.

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au

About TruPharma

TruPharma, LLC is a front-end pharma sales and marketing company focused on commercializing branded and generic prescription drugs for the U.S. Market. TruPharma has a diverse portfolio of products distributed across multiple channels. TruPharma is operated by a team of experienced executives focused on getting complex products FDA-approved and into the market. For more information: www.trupharma.com

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au